We believe that INBRX-106 can outperform bivalent agonists and has the potential to be widely used in combination with approved checkpoint inhibitors and also effective in tumors non-responsive to approved checkpoint inhibitors.
the Candidate
Our hexavalent OX40 agonist.
Hexavalent engagement of OX40 is designed to:
- Engage multiple OX40 receptors and promote hyperclustering.
- Enhance activation of the OX40 costimulatory pathway without the need for Fc crosslinking.
- Promote proliferation of activated T-cells.
- Enhance T-cell functionality.
- Induce reversal of regulatory T-cell–mediated immune suppression.
Going Beyond the Bivalent Approach
INBRX-106 Clinical Trials
The global, randomized, phase 2/3 study (NCT06295731) is evaluating INBRX-106 + pembrolizumab vs pembrolizumab alone as first-line therapy for patients with treatment-naive HNSCC and high PD-L1 expression (combined positive score [CPS] of ≥20).
The ongoing phase 1/2 study (NCT04198766) is evaluating INBRX-106 in combination with pembrolizumab in various solid tumors including NSCLC and HNSCC.